Lineage Cell Therapeutics (LCTX) Stock: Buy, Sell, or Hold?
LCTX - Lineage Cell Therapeutics, Inc.
$1.03
0.08 (8.70%)
▲
5d:
+13.91%
30d:
+0.0%
90d:
-19.53%
BUY
HIGH Confidence
Analysis Updated: Oct 8, 2026 12:00 AM ET
Earnings: Nov 05, 2026
27d
Get Alerted When LCTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: LCTX shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: LCTX shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: LCTX is currently trading at $1.03, which is considered fair relative to its 30-day fair value range of $0.95 to $1.08.
Technical Outlook: Technically, LCTX is in a strong downtrend. The price is approaching resistance at $1.04. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 8.7% recently.
Market Sentiment: LCTX scores 78/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $5.50 (+480.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, LCTX is in a strong downtrend. The price is approaching resistance at $1.04. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 8.7% recently.
Market Sentiment: LCTX scores 78/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $5.50 (+480.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.95 -
$1.08
Company Quality Score
68/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
92.1%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (78/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+8.7%)
- BULLISH: Trading 480.4% below Wall St target ($5.50)
- BULLISH: Bottoming setup score 78/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$0.95 -
$1.08
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.88
Resistance Level
$1.05
Current Trend
Strong Downtrend
Technical data as of
Oct 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.89
Wall Street Target
$5.50
(+480.4%)
Revenue Growth (YoY)
-61.3%
Profit Margin
-246.6%
Share & Embed Analysis
Last updated: October 08, 2026 4:35 PM ET
Data refreshes hourly during market hours. Next update: 5:35 PM
Data refreshes hourly during market hours. Next update: 5:35 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LCTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 49 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 47 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
14 analysts |
$146 | 60 BUY |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
19 analysts |
$18 | 42 HOLD |
|
RLAY
Relay Therapeutics Inc |
STRONG BUY
13 analysts |
$28 | 58 HOLD |
